![Neratinib with or without Immune Checkpoint Inhibitors in Fibrolamellar Carcinoma](https://oncodaily.com/pub/uploads/2024/07/R0UcYe3y_400x400-e1721040089373.png)
Neratinib with or without Immune Checkpoint Inhibitors in Fibrolamellar Carcinoma
Arndt Vogel shared a post on X:
“Neratinib Alone or with Immune Checkpoint Inhibitors with or without mTORi in Fibrolamellar Carcinoma Liver Cancer.
15 pts, interesting study design, benefit for some Really difficult to treat cancer, we need to do better.”
Authors: Ghassan K. Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A. Piha-Paul, Joseph S. Light, Scott Sherrin, Amin Yaqubie, Alison Clemens O’Neill, James J. Harding, Raed Al-Rajabi, Crystal S. Denlinger, Pablo Cano, Albert S. Cornelius, Eileen M. O’Reilly, Daniel DiPrimeo, Lisa D. Eli, John D. Gordan, and David B. Solit.
Source: Arndt Vogel/X
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.